PANTOPRAZOLE SODIUM (pantoprazole sodium) by Deva Holdings is (h, k)-atpase enzyme system at the secretory surface of the gastric parietal cell. Approved for older for the short-term treatment (up to 8 weeks) in the healing, symptomatic relief of erosive esophagitis (ee). First approved in 2025.
Drug data last refreshed 20h ago
(H, K)-ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus. The binding to the (H, K)-ATPase results in a duration of antisecretory effect that persists longer…
Worked on PANTOPRAZOLE SODIUM at Deva Holdings? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Efficacy and Safety of L-Pantoprazole Sodium Injection to Treat Upper Gastrointestinal Ulcer Bleeding
Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD
Bioequivalence Study of Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition
Bioequivalence Study of Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddy's Laboratories Limited Under Fed Condition
Pantoprazole Sodium 40 mg DR Tablets Under Fasting Conditions